#diaceutics

[oncozine]

Accelerate the Development of Precision Medicine Diagnostics

[kings-research]

Clinical Laboratory Services Market Report Forecast by Development, Trends, and Future Forecast.

Introduction

Clinical Laboratory Services refer to the type of diagnostic material extracted from the human body for the purpose of diagnosis, prevention, or treatment. The rising incidence of chronic diseases globally is driving the market growth globally.

The product is developing rapidly to ensure result accuracy, to identify biomarkers of several diseases. For instance, as per Globocan 2020 statistics, there were more than 19,292,000 new cancer cases diagnosed worldwide in 2020 itself.

The rising prevalence of chronic diseases, as well as the growing demand for accurate and timely disease diagnostics, are driving the market. Due to the general growing prevalence of the targeted diseases, prominent players are focusing on technological developments in their products to get a competitive advantage over their competitors.

Get More Information about Clinical Laboratory Services@ https://www.kingsresearch.com/post/clinical-laboratory-services?utm_source=Atish

COVID-19 Impact

The pandemic induced healthcare crisis has positively impacted the clinical laboratory services market. Spikes in COVID-19 infection rates resulted in mass testing worldwide. This resulted in manufacturers enhancing their current production capacity to meet the massive demand for testing kits and other diagnostic solutions.Several market giants are also developing their product range to deliver higher accuracy in results and better diagnosis.

Key Developments

The market is developing rapidly along with integration of technology to keep up with latest industry trends. For example, in July 2021, Deep Bio, a prominent player in artificial intelligence (AI) cancer diagnostics, is collaborating with ARUP Laboratories. This collaboration is expected to further their goals of cancer diagnostics using AI.

Independent laboratories have a great opportunity in densely populated and developing nations like India and China, where a large portion of the population lack access to proper medical diagnostic services. According to the National Accreditation Board for Testing and Calibration Laboratories (NABL), there were around 6200 NABL certified medical labs in India as of November 2020.

Also, in July 2020, Diaceutics PLC, a company focused on diagnostic network solutions for the development and commercialization of precision medicine diagnostics, patterned with Targos Molecular Pathology and HistoCyte Laboratories to enhance and expand diagnostic testing services in 2,500 labs worldwide. All these developments are fuelling the segment growth and driving the overall market.

Diaceutics PLC, a company focused on diagnostic network solutions for the development and commercialization of precision medicine diagnostics, also partnered with Targos Molecular Pathology and HistoCyte Laboratories in July 2020 to enhance and expand diagnostic testing services in 2,500 labs around the world. All of these trends are boosting the overall market and fueling market expansion.

Competitive Landscape

Global firms control a large portion of the industry, but local companies are also focusing on providing innovative services to the public, allowing them to create a significant presence in this market. With the growing need for technology, few new entrants are projected to enter the market in the future, and existing companies will gain a significant share of the market.

Several prominent players of the market include:

●        Amedes Holding GmbH

●        Quest Diagnostics Incorporated

●        Eurofins Scientific

●        UNILABS

●        Sonic Healthcare

●        Abbott

●        NeoGenomics

●        ARUP Laboratories

About Us

Kings Research is a data proficient market research firm that specializes in fostering efficient insights that propels businesses. We specialize in providing business intelligence on product specific markets to gain insights on quantifiable data. And our aim is to be the development catalyst to our clients that deliver actionable insights.

[pharmaphorumuk]

AI healthcare companies set for exponential growth – report

Companies specialising in artificial intelligence (AI) in healthcare are in “rude health” and are set for exponential growth over the next five years, according to a new report.

The report by adviser and broker finnCap outlines the companies that are employing AI to its best advantage and where its application should have a meaningful business benefit.

AI has potential applications across life sciences, including drug discovery, clinical trials and patient care, in addition to potential improvements in speed and efficiency of company operations.

Many trials are still unsuccessful because drugs fail to show efficacy and safety and AI is seen as a way of improving the chances of success by screening for various factors that could affect outcomes.

The global market was worth $2.1bn in 2018, with exponential growth to $36.1bn predicted by 2025, at a combined annual growth rate of 50.2%.

AI presents various new challenges, and the pharmaceutical industry has highlighted many technologies in the past that promised to drive productivity, but nothing has yet worked on a large scale.

Nevertheless, the authors believe that AI is likely to become a greater differentiator in the next 5-10 years and the report presents case studies and real-world examples of the benefits it could provide.

Findings came shortly after Exscientia claimed a world first by bringing the first AI-designed drug into a clinical trial in partnership with Sumitomo Dainippon Pharma.

The healthcare sector is particularly primed to benefit from AI because it deals with large amounts of data on a daily basis – in 2020 the amount of health data is expected to double every 73 days.

The report’s authors outline four key factors why they consider the AI in healthcare sector to be an attractive one for investment.

First, is the advances in computing power and decline in hardware cost, which will continue to increase the capability of AI and reduce the costs of its implementation.

Second, the continually increasing size of data sets generated in the healthcare field, which AI can allow for improved processing and management of data.

Third, is the number of cross-industry partnerships and collaborations in the healthcare sector which have grown and are expected to continue to do so.

All of the main big pharma companies have either expressly collaborated with or acquired AI technologies to take advantage of the opportunities AI brings to the table.

Fourth, is the competitive advantage which AI offers in terms of processes and efficiency to the companies employing it, over the companies that are not yet implementing the technology.

Companies to watch highlighted in the report are Sensyne Health, DeepMatter Group, 4D Pharma, Integumen, Fusion Antibodies, RenalytixAI, Diaceutics, Oxford Biodynamics, e-therapeutics, and Medica Group.

The post AI healthcare companies set for exponential growth – report appeared first on .

from https://pharmaphorum.com/news/ai-healthcare-companies-set-for-exponential-growth-report/

[americanfreighttrucking]

Diagnostics Data Analytics Company Diaceutics to List on London Stock Exchange

Diagnostics Data Analytics Company Diaceutics to List on London Stock Exchange

Company seeking £53M IPO on London Stock Exchange junior market, AIM (Alternative Investment Market)

Diaceutics expects the addressable market for its specific services to grow to US$2.5BN by 2023

PARSIPPANY, N.J.–(BUSINESS WIRE)–Diaceutics plc, a revenue-generating and profitable diagnostics data analytics and implementation services company which services the global pharmaceutical industry,…

[pharmamktnet]

Diaceutics Research Finds Cancer Patients Face Delays Getting Potentially Lifesaving Biomarker Tests BELFAST, Northern Ireland--(BUSINESS WIRE)--Diaceutics, the diagnostics data analytics and implementation services company, today announces that it is partnering with the Union for International Cancer Control (UICC) as a Visionary Partner of World Cancer Day, a global initiative led by UICC annually on 4th February.

[digitallyunpluggedmagazine]

Diaceutics Opens Asian Hub to Capitalize on Growing Market SINGAPORE--(BUSINESS WIRE)--Diaceutics opens Asian hub to improve patient access to targeted therapies

[geraldlocke]

Diaceutics Ryan Keeling named in prestigious pharma list

Diaceutics has announced that its Chief Innovation Officer, Ryan Keeling, has been listed as a pharmaceutical industry leader in the prestigious PharmaVOICE 100. Keeling was recognised by PharmaVOICE for his commitment to helping more patients get access to precision medicine drugs by resolving issues with diagnostic testing. PharmaVOICE is a monthly publication covering news and developments …

Source

from https://www.trendstoday.com/technology/diaceutics-ryan-keeling-named-in-prestigious-pharma-list.html from https://trendstoday0.tumblr.com/post/626519781002166272 from https://geraldlocke.blogspot.com/2020/08/diaceutics-ryan-keeling-named-in.html

[maryfrale0]

Diaceutics Ryan Keeling named in prestigious pharma list

Diaceutics has announced that its Chief Innovation Officer, Ryan Keeling, has been listed as a pharmaceutical industry leader in the prestigious PharmaVOICE 100. Keeling was recognised by PharmaVOICE for his commitment to helping more patients get access to precision medicine drugs by resolving issues with diagnostic testing. PharmaVOICE is a monthly publication covering news and developments …

Source

from https://www.trendstoday.com/technology/diaceutics-ryan-keeling-named-in-prestigious-pharma-list.html from https://trendstoday0.blogspot.com/2020/08/diaceutics-ryan-keeling-named-in.html from https://maryfraley.blogspot.com/2020/08/diaceutics-ryan-keeling-named-in.html

[trendstoday0]

Diaceutics Ryan Keeling named in prestigious pharma list

Diaceutics has announced that its Chief Innovation Officer, Ryan Keeling, has been listed as a pharmaceutical industry leader in the prestigious PharmaVOICE 100. Keeling was recognised by PharmaVOICE for his commitment to helping more patients get access to precision medicine drugs by resolving issues with diagnostic testing. PharmaVOICE is a monthly publication covering news and developments …

Source

from https://www.trendstoday.com/technology/diaceutics-ryan-keeling-named-in-prestigious-pharma-list.html

[anewsbuddy]

MIDAS SHARE TIPS: Induction Healthcare

MIDAS SHARE TIPS: Induction Healthcare

[ad_1]

Prime Minister Boris Johnson put healthcare at the heart of his multi-billion pound spending plan last week. That does not just mean building more hospitals, but also using technology to help them work more effectively.

Induction Healthcare and Diaceutics are at the forefront of these efforts.

Every year, the NHS loses around £1billion from outpatients missing their appointments. Some…

[sammfeaster]

Medical data firm Diaceutics announces AIM float with expected £53m valuation

Funds will be used to acquire more data sets and develop AI analysis. from MobiHealthNews https://www.mobihealthnews.com/content/medical-data-firm-diaceutics-announces-aim-float-expected-%C2%A353m-valuation via IFTTT

[devnasirali]

Diaceutics Raises $5M from WhiteRock Capital Partners and Silicon Valley Bank to Support Global Expansion

Diaceutics Raises $5M from WhiteRock Capital Partners and Silicon Valley Bank to Support Global Expansion

The investment will assist the corporate building up its international footprint and world succeed in Financing will permit Diaceutics to boost up product building, supply extra enhance to pharmaceutical shoppers and make stronger affected person trying out PARSIPPANY, N.J.–(BUSINESS WIRE)–April five, 2018– Diaceutics, the diagnostic commercialization corporate that improves affected person…

[metabloks]

Diaceutics Raises $5M from WhiteRock Capital Partners and Silicon Valley Bank to Support Global Expansion https://ift.tt/2q7NzWN

[tomhalter]

Intel, Lenovo and Diaceutics Unlocking the...

At #HIMSS18, Intel unveils a collaboration with @Lenovo and @Diaceutics that will allow doctors and health care providers to harness the power of #AI to transform patient diagnostic testing. #IamIntel

Intel, Lenovo and Diaceutics Unlocking the...

At the Healthcare Information and Management Systems Society (HIMSS) Conference 2018, Intel unveiled a collaboration with Lenovo and Diaceutics that will allow doctors and health care providers to harness the power of artificial intelligence (AI) to transform patient diagnostic testing and improve treatment.

Intel Business Social Hub

[pharmamktnet]

Diaceutics Invests Additional £1 Million in Patient Data to Improve Outcomes

Diaceutics Invests Additional £1 Million in Patient Data to Improve Outcomes

BELFAST, Northern Ireland–(BUSINESS WIRE)–<a href="https://twitter.com/hashtag/DataAnalytics?src=hash&quot; target="_blank">#DataAnalytics</a>–Diaceutics is expanding its global data lake with the acquisition of 16 million additional patient records per annum. http://www.businesswire.com/news/home/20190617005458/en/Diaceutics-Invests-Additional-%C2%A31-Million-Patient-Data/?feedref=JjAwJuNHiystnC…